Published: 14th Sep, 2020
The National Immunogenicity and Biologics Evaluation Centre (NIBEC) for assessing clinical immunogenicity of viral vaccines, especially the ones in the pipeline for Covid-19, has been inaugurated.
Context
The National Immunogenicity and Biologics Evaluation Centre (NIBEC) for assessing clinical immunogenicity of viral vaccines, especially the ones in the pipeline for Covid-19, has been inaugurated.
About
- Established jointly by Bharati Vidyapeeth University through its constituent unit Interactive Research School for Health Affairs (IRSHA) and BIRAC-DBT, Government of India through National Biopharma Mission, the facility was inaugurated virtually in an e-inauguration ceremony.
- NIBEC, established in about 10,000 sq ft, has one BSL-3+, 4 BSL-2 and 10 BSL-1 laboratories.
- Evaluation tests: Key immunogenicity evaluation tests like Plaque Reduction Neutralization Test (PRNT), Microneutralisation assay, IgM and IgG ELISA, developed, standardised and validated for dengue, chikungunya and SARS-CoV-2 viruses.
What is National Biopharma Mission?
- The Mission Programme is a Pan-India Programme with the main aim of making India a hub for design and development of novel, affordable and effective biopharmaceutical products and solutions.
- It is an Industry-Academia Collaborative Mission of Department of Biotechnology (DBT) for Accelerating Early Development for Biopharmaceuticals.
- The mission is implemented by Biotechnology Research Assistance Council (BIRAC).
|
Biotechnology Industry Research Assistance Council (BIRAC)
|
Significance of the development
- Vaccine development requires extensive evaluation in humans to establish safety, immunogenicity and clinical efficacy. Centralised viral and bacterial clinical immunogenicity labs meeting the stringent standards is a critical need for the vaccine industry.
- Domestic capabilities maintaining international standards in this space will accelerate and fast-track the development of indigenous vaccines in India.
Courses
Study
Notes
Home
Resources
More
